TooTall was pushing AVXL. It, with one drug in phase 1 safety trials in Australia, with a small number of patients enrolled, now has a higher market cap than CTIX, with its 3 drugs in human trials for 4 indications, with large numbers of people enrolled, and much further along in trials for all drugs except Prurisol, where it's at about the same point as AVXL's drug.

Sold some of my AVXL so I could buy more CTIX. In fairness -- AVXL could be a huge huge winner IF their Alzheimer drug works -- I mean, mega-huge -- and the new CEO (first good one they've had) has somewhat de-risked the investment by also trying the drug for epilepsy -- seems promising for that, so even if the Alzheimer's thing doesn't work, they have a fall-back. I'm not criticizing them for their (small) market cap. I'm just pointing out how crazy CTIX valuation is here.